logo
Plus   Neg
Share
Email

Bristol-Myers Squibb Raises Earnings Guidance - Quick Facts

Bristol-Myers Squibb Company (BMY) said its second-quarter results were highlighted by strong sales for Eliquis (apixaban) and Opdivo (nivolumab) and a robust operating performance across the portfolio. The company increased its fiscal 2019 financial guidance.

For 2019, the company now expects non-GAAP EPS in the range of $4.20 - $4.30, revised from prior guidance range of $4.10 - $4.20. Analysts polled by Thomson Reuters expect the company to report profit per share of $4.16. Analysts' estimates typically exclude special items.

For the second-quarter, non-GAAP net earnings attributable to Bristol-Myers Squibb was $1.9 billion, or $1.18 per share, compared to $1.6 billion, or $1.01 per share, a year ago. On average, ten analysts expected the company to report profit per share of $1.06 for the quarter.

Second-quarter revenues were $6.3 billion, an increase of 10% compared to the same period a year ago. Revenues increased 13% when adjusted for foreign exchange impact. Analysts expected revenue of $6.11 billion for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT